Chinese drug could help battle deadly Nipah virus

Key Concepts

• Nepa Virus: A highly fatal (40-75% fatality rate) viral disease with no current approved treatment or vaccine.
• VV116: An oral antiviral drug originally developed for COVID-19, now showing potential efficacy against the Nepa virus.
• Viral Vector Vaccine (Oxford Vaccine): A vaccine currently in Phase 2 clinical trials, utilizing the same technology as the Oxford-AstraZeneca COVID-19 vaccine.
• Supportive Care: The current standard of care for Nepa virus, focusing on alleviating symptoms rather than directly combating the virus.

Nepa Virus & Potential Treatments: A Report from SEMP China

The emergence of the Nepa virus, with a fatality rate ranging from 40 to 75%, has prompted increased surveillance at Asian airports following an outbreak in India’s West Bengal state. Currently, no approved treatments or vaccines exist for human use, with patient care limited to supportive measures. However, Chinese researchers are reporting promising results with the antiviral drug VV116.

VV116: From COVID-19 Treatment to Nepa Virus Potential

VV116 is an oral antiviral drug initially developed by researchers from the Wuhan Institute of Urology, alongside other institutes, as a treatment for COVID-19. It has already received approval for COVID-19 treatment in mainland China and Uzbekistan. Recent research, published late last year, indicates VV116’s potential efficacy against the Nepa virus.

Specifically, studies conducted on hamsters demonstrated a significantly improved survival rate. Approximately two-thirds of hamsters administered VV116 survived exposure to a lethal dose of the virus, suggesting the drug could substantially increase survival chances in infected individuals. Researchers propose VV116 could be utilized both for treating infected patients and as a prophylactic measure for high-risk individuals, such as medical personnel, potentially hindering the virus’s spread.

Administration & Safety of VV116

VV116 is administered orally, in pill form, making it a relatively straightforward medication to use. Crucially, the drug has already been proven safe for human consumption through its existing application in COVID-19 treatment. This established safety profile could expedite potential approval for use against the Nepa virus.

Significance in Controlling the Spread

The lack of current approved treatments or vaccines for the Nepa virus means that care is currently limited to supportive measures. This approach is challenging for patients due to the high mortality rate and facilitates further viral transmission. The availability of a drug like VV116 could significantly curb the spread of the virus and improve patient outcomes while longer-term solutions, such as a vaccine, are developed. As stated by the reporter, “with a drug to help treat it, it could help stop the spread as easily and it could just make it you know better for patients who get it while we work towards something like a vaccine.”

Current Research & Future Prospects

While the potential of VV116 is promising, the drug approval process is lengthy, and it remains uncertain whether it will be approved for use in India or elsewhere. Parallel research efforts are focused on vaccine development. A vaccine developed by the University of Oxford has entered Phase 2 human clinical trials in Bangladesh as of December. This vaccine utilizes the same viral vector technology as the Oxford-AstraZeneca COVID-19 vaccine.

The reporter emphasized the importance of both approaches, stating, “having drugs that could help treat the virus are going to be very important to help uh, patients and help stop the spread.”

Technical Terms

• Antiviral Drug: A medication used to treat viral infections.
• Viral Vector Vaccine: A type of vaccine that uses a modified virus (the vector) to deliver genetic material from the target virus to the body’s cells, triggering an immune response.
• Phase 2 Clinical Trial: A stage of clinical research that evaluates the effectiveness and side effects of a new treatment in a larger group of people.
• Prophylactic: A preventative measure taken to reduce the risk of disease.
• Supportive Care: Medical treatment focused on relieving symptoms and improving quality of life, rather than curing the underlying disease.

Conclusion

The Nepa virus outbreak presents a significant public health challenge due to its high fatality rate and lack of existing treatments. VV116, an oral antiviral drug originally developed for COVID-19, offers a potentially valuable therapeutic option, demonstrating promising results in preclinical studies. Alongside ongoing vaccine development efforts, such as the Oxford University vaccine currently in Phase 2 trials, VV116 represents a crucial step towards mitigating the impact of this deadly virus.